German-Austrian recommendations for the antiretroviral therapy of HIV-infection (Status May 2004)

European Journal of Medical Research

Volumn 9, Issue 11, 2004, Pages 491-504

  Salzberger, B ^a   Marcus, U ^a   Vielhaber, B ^a   Arasteh, K ^a   Golz J ^a   Brockmeyer, N H ^a,b   Rockstroh, J ^a   Arendt, G ^a   Bader, A ^a   Behrens, G ^a   Beichert, M ^a   Berg, T ^a   Bergmann, F ^a   Bieniek, B ^a   Blauhut, B ^a   Bogner, J ^a   Bockhaus, W ^a   Brodt, H R ^a   Buscher U ^a   Buhk, T ^a   Christensen, S ^a   Docrr, H W ^a   Dupke, S ^a   Esser, S ^a   Fleckenstein, B ^a   Funk, M ^a   Gantke, B ^a   Gellermann, H J ^a   Goebel, F D ^a   Gotzenich A ^a   Grosch Worner I ^a   Gurtler L ^a   Haberl, A ^a   Haerter, G ^a   Harrer, T ^a   Hartmann, M ^a   Helm, E B ^a   Heise, W ^a   Hoffmann, C ^a   Hower, M ^a   Husstedt, I ^a   Jablonowski, H ^a   Jagel Guedes E ^a   Jager H ^a   Karwat, M ^a   Kerkau, T ^a   Kern, P ^a   Klinker, H ^a   Klufer P ^a   Knechten, H ^a   Korn, K ^a   Korner T ^a   Krausslich H G ^a   Kramer, A ^a   Kremer, H ^a   Kreuter, A ^a   Kurowski, M ^a   Mauruschat, S ^a   Muller N ^a   Mutz, A ^a   Oette, M ^a   Pfeil, B ^a   Plettenberg, A ^a   Rasokat, H ^a   Reimann, G ^a   Rieger, A ^a   Rieke, A ^a   Rothe, C ^a   Ruf, B ^a   Ruhnke, M ^a   Rump, J A ^a   Shah, P ^a   Schafberger, A ^a   Schedel, I ^a   Schewe, K ^a   Schottmann, R ^a   Schmaloer D ^a   Schmied, B ^a   Schmidt, B ^a   Schmidt, R E ^a   Schneider, T ^a   Schofer H ^a   Schranz, D ^a   Sonnenberg Schwan, U ^a   Staszewski, S ^a   Stellbrink, H J ^a   Stocker, H ^a   Stoehr, A ^a   Stoll, M ^a   Tschachler, E ^a   Uberla K ^a   Ulmer, A ^a   van Lunzen, J ^a   Vetter, N ^a   Vocks Hauck, U ^a   Walker, U A ^a   Weber, S ^a   Werner, A ^a   Wolf, E ^a   Wolf, H ^a   Zangerle, R ^a   Zeitz, M ^a   Zippel, S ^a   more..

^a Ruhr Universität ^*

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; AUSTRIA; CLINICAL TRIAL; DRUG EFFECT; GERMANY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTICENTER STUDY; PRACTICE GUIDELINE;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUSTRIA; GERMANY; HIV INFECTIONS; HIV-1; HUMANS;

EID: 13844312888     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Mellors JW, Munoz A, Giorgi JV, et al.: Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
2. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced, HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543-9.
3. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
4. Palella FJ, Jr., Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
5. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA: Prognosis of HlV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
6. Raboud JM, Montaner JS, Conway B, et al.: Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998; 12:p1619-24.
7. Kempf DJ, Rode RA, Xu Y, et al.: The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12:F9-Fl4.
8. Clavel F, Hance AJ. HIV drug resistance. N Eng J Med 2004; 350: 1023-35.
9. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 2003; 139:810-6.
10. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37:1112-8.
11. Phillips AN, Cozzi Lepri A, Lampe F, Johnson M, Sabin CA: When should antifetroviral therapy be stated for HIV infection? Interpreting die evidence from observational studies. AIDS 2003; 17: 1863-69
12. d'Arminio Monforte A, Testa L, Adorni F, et al.: Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998; 12:1631-7.
13. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME; Antiretroviral Therapy Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-86
14. Kinloch-De Loes S, Hirschel BJ, Hoen B, et al.: A controlled trial of zidovudine in primary human inununodeficiency virus infection. N Engl J Med 1995; 333:408-13.
15. Undbäck S, Vizzard J, Cooper DA, Gaines H: Long-term prognosis following Zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. JID 1999; 1791:1549-52.
16. Kaufmann D, Lichterfeld M, Altfeld M, Allen T, Johnston M, et al. Limited durability of immune control following treated acute HIV infection. 11th CROI, San Francisco 2004, Abstr. 24
17. Hoen P, Fournier I, Charreu I, Lacabaratz C, Burgard M, et al. Structured Treatment Interruptions in-primary HIV infection: final results of the multicenter prospective PRIMSTOP pilot trial. llth CROI, San Francisco 2004, Abstr. 395
18. Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JM. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 2004; 18: 709-18
19. Williams I, Asboe D, Babiker A, Goodall R, Hooker M, et al. A virological benefit from an induction/maintenance strategy compared with a standard 3-drug regimen in antiretroviral naive patients: the FORTE trial. 11th CROI, San Francisco 2004, Abstr. 564
20. Shafer RW, Smeaton LM, Robbins GY, De Gruttola V, Snyder SW, D'Aquila RT, et al.: Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Eng J Med 2003; 349: 2304-15
21. Kempf DJ, King MS. Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E J. Incidence of resistance in a double-blind study compiring lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Infect Dis. 2004; 189:51-60.
22. Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fatkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H; Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/ Indinavir Study Group. AIDS 2000; 14:1181-5
23. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD; MaxCmnin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCminl Trial. J Infect Dis 2003; 188:635-42
24. Youle M., Gerstoft J., Fox Z., Losso M., Jayaweera D.T., Rieger A., Bruun J.N., Castagna A., Walmsley S., Hill A., Dragsted U.B. and Lundgren J.D. for the MaxCmin2 trial group. The final Week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ ritonavir (1000/100 mg bid): The MaxCmin2 trial. 9th European AIDS Conference, Warsaw 25-29 October 2003, Abstr. F11/3
25. Stszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341:1865-1873
26. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al.: Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Eng J Med 2003; 349: 2293-303
27. Van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, et al.: A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected patients. AIDS 2003; 17: 987-999
28. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavitenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63
29. Taylor S, Allen S, Fidler S, White D, Gibbons S, et al. Stop Study- After discontinuation of Efavirenz, plasma concentrations may persist for 2 weeks or longer. 11th CROI, San Francisco 2004, Abstr. 131
30. Yerly S, Fagard C, Gunthard HF, Hirschel B, Perrin L; Swiss HIV Cohort Study. Drug resistance mutations during structured treatment interruptions. Antivir Ther 2003; 8:411-5
31. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W; CNAAB3005 International Study Team. Abacavir-lamivadine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001; 285:1155-63.
32. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR, et al. Triple-nucleoside regimens versus Efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Eng J Med 2004; 350:1850-61
33. Gallant JE, Rodriguez A, Weinberg W, et al. Early nonresponse to tenofovir DF (TDF) + Abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC + 3TCz ESS30009 unplanned interim analysis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 16, 2003. (Abstract H-1722a).
34. Jemsek J, Hutcherson P, Harper E. Poor Virologic Responses and Early Emergence of Resistance in Treatment Naive, HIV-infected Patients Receiving a Once Daily Triple Nucleoside Regimen of Didanosine, Lamivudine, and Tenofovir DF. 11th Conference on Retrovirus and Opportunistic Infections, San Francisco, CA, February 8-11, 2004, Abstract 51
35. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen I, Nielsen H, Katzenstein TL, Lundgren JD. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 2003; 17:2045-52
36. Squires KE, Thity A, Giordano M, for the A1424-034 International Study Team. Atazanavir QD and efavirenz QD with fixed-dose ZDV+3TC: Comparison of antiviral efficacy and safety through wk 24 (A1424-034). 42nd ICAAC 2002, San Diego, Abstract H-1076
37. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chermother 1997 Mar;41(3):654-60.
38. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999. 13: p. 213-224
39. Stephan C, v.Hentig N, Kourbeti I, Dauer B, Mösch M, Lutz T, Klauke S, Harder S, Kurowski M, Staszewski S. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18: 503-08.
40. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-1734.
41. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-408.
42. DeGruttola V, Dix L, A'Aquila R, et al. The relationship between baseline HIV drug resistance and response to andretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:43-50
43. Durant J, Clevenbergh F, Halfon F, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-2199
44. Baxter JD, Mayers DI, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000;14:F83-93
45. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-379
46. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002;16:209-218
47. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S. Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM; VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579-88
48. Meynard JL, Vray M, Morand-Joubert L, et al. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antivir Ther 2000; 5 suppl 3:67-68.
49. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, et al. Long-term efficacy of routine access to antiretroviral-resigtance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 2004; 38: 723-30
50. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The Euro Guidelines Group for HIV resistance. AIDS 2001;15:309-320.
51. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-28
52. Wensing AMJ, van de Vijver DAMC, Asjo B, Balotta C, Camacho R, de Luca A, de Mendoza C, et al. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: the CATCH-Study. 2nd IAS Conference, Paris 2003, Abstr. LB01
53. Duwe S, Brunn M, Altmann D, et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconvertef Study. J Acquir Immune Defic Syndr 2001;26:266-273.
54. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Colher AC, Koup RA, Mellors JW, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Eng J Med 2002; 347: 385-94
55. Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, Délia S, Chiodo F, Ghinelli F, Bertoli A, d'Arminio Monforte A, Perno CF, Moroni M, Balotta C. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004; 18: 227-35
56. Cane P, Dean G, Fisher M, Pao D, Drake S, Pillay D, et al. Persistence of primary genotypic resistance following HIV-1 seroconversion for as long as 3 years post-infection. 11th CROI, San Francisco 2004, Abstr. 684
57. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999;19:708-712
58. Alexander CS, Asselin JJ, Ting LS, Montaner JS, Hogg RS, Yip B, O'Shaughnessy MV, Harrigan PR. Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis 2003; 188:541-8
59. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 2003; 63:741-53
60. Mallon PW, Ray J, Cooper DA. Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. J Clin Virol 2003; 26:223-7
61. A L Rendon, M Nunez, D Gonzalez-Requena, I Jimenez Nacher, J Gonzalez-Lahoz, and V Soriano. The Benefit of Treatment Interventions Driven by Therapeutic Drug Monitoring. 11th CROI, San Francisco 2004, Abstr. 567
62. Becher F, Landman R, Mboup S, Toure Kane CN, Canestri A, Liegeois F, Vray M, Prevot M-H, Leleu G, Benech H. Monitoring of didanosine and stavurline intracellular triphosporylated anabolite concentrations in HIV-infected patients. AIDS 2004; 18: 181-87
63. Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, et al.: Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17: F33-F37
64. Fagard C, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B; Swiss HrV Cohort Study. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 2003; 163:1220-6
65. Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G,. Yoder C, Ehler L, Sklar PA, Belson M, Hidalgo B, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Fauci AS. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immmunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003;188: 388-96
66. Niehues T, Wintergerst U, Funk M, Notheis G et al: Empfehlungen zur antiretroviralen Therapie bei HIV-infizierten Kindern. Monatsschr Kinderheilkd 2001;149: 1372-82.
67. Deutsch-Österreichische Empfehlungen zur HIV-Therapie in der Schwangerschaft. Aktualisierung Mai 2003. http://www.rki.de/INFEKT/ AIDS_STD/BR-LINIE/BR-LINIE.HTM
68. Postexpositionelle Prophylaxe nach HIV-Exposition. Deutsch-Österreichische Empfehlungen. Aktualisierung Mai 2002.